Background {#Sec1}
==========

Selected patients with cardiac rhythm management devices (CRMD) can safely undergo cardiovascular magnetic resonance (CMR). However, susceptibility artifacts from CRMD generator and leads can affect image quality, limiting the information provided by CMR. We sought to evaluate whether CMR of CRMD patients can provide clinically useful information that includes answering the clinical question, providing new findings, new diagnoses, or change in clinical management.

Methods {#Sec2}
=======

We studied 89 patients with CRMD who were evaluated for CMR from November 2012 through June 2015. Eighteen patients were excluded for various MRI contraindications. The remaining 71 patients completed the scan without complications. All CRMD were interrogated prior to the scan. For pacemaker dependent patients, asynchronous pacing was used during CMR. Device therapies were turned off for implantable cardioverter defibrillator (ICD) patients. CMR images were acquired on a 1.5 Tesla (Siemens Aera) scanner using standard sequences including single shot black blood imaging, cine with SSFP or FLASH, first pass perfusion, and late gadolinium enhancement (LGE). During the scan, patients were monitored with continuous vitals, ECG, oximetry, and voice contact. All CRMD were re-interrogated after the scan and original settings were restored. Images were evaluated using CMR^42^ (Circle Cardiovascular Imaging) software.

Results {#Sec3}
=======

Baseline characteristics are listed in Table [1](#Tab1){ref-type="table"}. ICD was present in 58 (81.7%) and pacemaker in 13 (18.3%) patients. Common CMR indications included evaluation for ventricular arrhythmia substrate (n = 61), hypertrophic cardiomyopathy (HCM) (n = 6), and cardiac sarcoidosis (n = 4). Device artifact affected complete evaluation of myocardial segments in 17 patients (23.9%) on cine imaging and in 50 patients (70.4%) on LGE. CMR findings are summarized in Table [2](#Tab2){ref-type="table"}. The most common findings were non-ischemic scar (n = 24), ischemic scar (n = 17), and combined scar (n = 6), which helped guide ventricular arrhythmia ablation. Additionally, a new diagnosis or finding was made in 14 patients (19.7%), which included cardiac sarcoidosis (n = 3) and arrhythmogenic right ventricular cardiomyopathy (n = 2). In 3 HCM patients, CMR findings guided the decision for alcohol septal ablation vs. surgical resection. Overall, the clinical question was answered in 66 patients (92.9%).Table 1Baseline Clinical CharacteristicsAge (years)59.38 (± 12.95)Male59 (83.0%)Body mass index (kg/m2)29.54 (± 6.31)Body surface area (m2)2.09 (± 0.22)Coronary artery disease25 (35.7%)Diabetes mellitus9 (12.9%)Hypertension40 (57.0%)Hyperlipidemia37 (52.9%)Ischemic cardiomyopathy16 (22.9%)Non-ischemic cardiomyopathy24 (34.3%)Mixed cardiomyopathy6 (8.6%)Previous ventricular arrhythmia ablation24 (34.3%)Table 2CMR FindingsNon-ischemic scar24 (33.8%)Ischemic scar17 (23.9%)Combined ischemic and non-ischemic scar6 (8.5%)Hypertrophic cardiomyopathy4 (5.6%)Cardiac sarcoidosis3 (4.2%)Arrhythmogenic right ventricular cardiomyopathy (ARVC)3 (4.2%)Left ventricular involvement of ARVC2 (2.8%)Rejected cardiac sarcoidosis1 (1.4%)Rejected ARVC1 (1.4%)Accessory pulmonary vein1 (1.4%)Apical thrombus1 (1.4%)Pericardial lipomatosis1 (1.4%)Right ventricular pseudoaneurysm1 (1.4%)Severe aortic stenosis1 (1.4%)Subaortic membrane1 (1.4%)

Conclusions {#Sec4}
===========

Our results show that in carefully screened CRMD patients, CMR is safe, can answer the clinical question in vast majority of patients, and can provide new information to guide clinical management.
